Dicerna

Dicerna is a developer of investigational ribonucleic acid interference therapeutics for liver, cardiovascular and viral infectious diseases. Read more

Douglas M. Fambrough's photo - President & CEO of Dicerna

President & CEO

Douglas M. Fambrough

CEO Approval Rating

85/100

Founded:

2006

Status:

PublicIndependent CompanyNASDAQDRNA

DICERNA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Juno Therapeutics is Dicerna's #1 competitor. Juno Therapeutics's headquarters is in Seattle, Washington, and was founded in 2013. Like Dicerna, Juno Therapeutics also works within the Pharmaceuticals sector. Juno Therapeutics generates 59% of Dicerna's revenue.

Immune Design is one of Dicerna's top rivals. Immune Design was founded in Seattle, Washington} in 2008. Immune Design operates in the Pharmaceuticals industry. Compared to Dicerna, Immune Design generates $175.7M less revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is TESARO a competitor of Dicerna?

Dicerna Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$177.9M

Dicerna's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 111.5M. Over the last four quarters, Dicerna's revenue has grown by 17.7%. Specifically, in Q1 2021's revenue was $47.6M; in Q4 2020, it was $41M; in Q3 2020, it was $48.9M; in Q2 2020, Dicerna's revenue was $40.4M.

Dicerna Acquisitions

No recent acquisitions found related to Dicerna

Dicerna Funding History

Since Dicerna was founded in 2006, it has participated in 8 rounds of funding. In total Dicerna has raised $478.0M. Dicerna's last funding round was on Oct 2018 for a total of $100.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Oct 2018
$100M

Eli Lilly and Company

Private Placement
Mar 2017
$70M
IPO
Jan 2014
$90M
-
Series C
Jul 2013
$60M
Series B
Oct 2010
$4M

Since Dicerna was founded in 2006, it has participated in 8 rounds of funding. In total Dicerna has raised $478.0M. Dicerna's last funding round was on Oct 2018 for a total of $100.0M

Dicerna Investments

No recent investments found related to Dicerna

Dicerna News

May 13, 2021MarketScreener

to Participate in Upcoming Investor Conferences

(marketscreener.com) Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucle... See more »
April 8, 2021Markets Insider

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront

Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty i... See more »
April 1, 2021BioSpace

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2021

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference t... See more »
March 30, 2021MarketScreener

GalXC-Plus RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

(marketscreener.com) Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucle... See more »

Dicerna Press Releases

March 24, 2021centralcharts

Dicerna to Present New GalXC-Plus Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of inv... See more »
March 11, 2021Business Wire

Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will host a webinar on its alcohol use disorder (AUD) cand... See more »
February 18, 2021Business Wire

Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will release its fourth quarter and full year 2020 financi... See more »
November 16, 2020Business Wire

Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for First GalXC RNAi Candidate Under Companies' Global Research Collaboration and Licensing Agreement

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced FDA acceptance of the IND Application filed by L... See more »
November 5, 2020Business Wire

Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the third quarter... See more »
October 29, 2020Business Wire

Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it will release its Q3 2020 financial resul... See more »
October 1, 2020Business Wire

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company approved the grant of inducemen... See more »

Dicerna Videos

March 19, 2021Dicerna Youtube Channel

"Collaborating Across Teams" on YOUTUBE

March 19, 2021Dicerna Youtube Channel

"What is Dicerna?" on YOUTUBE

September 14, 2017Dicerna Pharmaceuticals Vimeo Channel

"Dicerna PHY Webinar_German_Final" on VIMEO

Cast: Dicerna Pharmaceuticals... See more »

Social Media

Dicerna Headquarters

75 Hayden Avenue

Lexington, Massachusetts02421

617-621-8097

Driving Directions »

Trending Companies

Dicerna Summary

ABOUT

Overview

Dicerna is a developer of investigational ribonucleic acid interference therapeutics for liver, cardiovascular and viral infectious diseases. Dicerna was founded in 2006. Dicerna's headquarters is located in Lexington, Massachusetts, USA 02421. It has...

CEO

Dicerna's President & CEO, Douglas M. Fambrough, currently has an approval rating of 85%. Dicerna's primary competitors are Juno Therapeutics, Immune Design & Kite Pharma.

Frequently Asked Questions about Dicerna

  1. When was Dicerna founded?

    Dicerna was founded in 2006
  2. Who is Dicerna's CEO?

    Dicerna's CEO is Douglas M. Fambrough
  3. How much revenue does Dicerna generate?

    Dicerna generates $177.9M in revenue
  4. How much funding does Dicerna have?

    Dicerna has historically raised $478M in funding
  1. Where is Dicerna's headquarters?

    Dicerna's headquarters is in Lexington Massachusetts, USA
  2. How many employees does Dicerna have?

    Dicerna has 78 employees
  3. What sector does Dicerna operate in?

    Dicerna is in Pharmaceuticals, Biotechnology
  4. Who are Dicerna's competitors?

    Dicerna's top competitors are Juno Therapeutics, Immune Design, Kite Pharma